Page 138 - Human Use News Today

On GPT-3: meta-learning, scaling, implications, and deep theory. The scaling hypothesis: neural nets absorb data & compute, generalizing and becoming more Bayesian as problems get harder, manifesting new abilities even at trivial-by-global-standards-scale. The deep learning revolution has begun as foretold.

TAIPEI, May 31, 2022 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the European Commission (EC) has approved the Marketing Authorization Application (MAA)

Investegate announcements from F. Hoffmann-La Roche Ltd, New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma

/PRNewswire/ -- Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis, Alzheimers,...

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 26, 2022 /PRNewswire/ -- Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such

Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis ...

  Approval follows CHMP recommendation for use in patients previously vaccinated with AstraZeneca COVID-19 vaccine or an EU-approved mRNA COVID-19

It is the first gene therapy to be directly administered into the brain to treat aromatic L-amino acid decarboxylase (AADC) deficiency - News - PharmaTimes

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine ...

Press release content from PR Newswire. The AP news staff was not involved in its creation.